Without delving too much into this, it seems to me (from what I have now read) that US FDA trials were not much more effort (time and money) than the Euro device trials
and it also seems to me that the FDA trials would be far more beneficial to the company in the long run
Considering that it seemed to be well established that device classification was a very grey area right from the very beginning, then I can only conclude this was a huge gamble (comparatively speaking) for very little benefit to TIS. The risk/reward simply wasn't worth it.
I know this is twenty twenty hindsight, but it seems pretty basic stuff for someone at the coalface to make a judgement call at the start, it seems to me all key information to decide this path of execution was well known
If what I am saying is true (and I'm not saying it is), then the board need to go in my opinion
- Forums
- ASX - By Stock
- TIS
- risk and reward
risk and reward
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TIS (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online